» Articles » PMID: 30545306

Diagnostic Value of Alpha-fetoprotein Combined with Neutrophil-to-lymphocyte Ratio for Hepatocellular Carcinoma

Overview
Publisher Biomed Central
Specialty Gastroenterology
Date 2018 Dec 15
PMID 30545306
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To investigate the diagnostic performance of alpha-fetoprotein (AFP) and neutrophil-to-lymphocyte ratio (NLR) as well as their combinations with other markers.

Methods: Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), AFP and levels as well as the numbers of neutrophils and lymphocytes of all enrolled patients were collected. The NLR was calculated by dividing the number of neutrophils by the number of lymphocytes. Receiver operating characteristic (ROC) curve analysis was conducted to determine the ability of each marker and combination of markers to distinguish HCC and liver disease patients.

Results: In total, 545 patients were included in this study. The area under the ROC curve (AUC) values for AFP, ALT, AST, and NLR were 0.775 (0.738-0.810), 0.504 (0.461-0.547), 0.660 (0.618-0.699), and 0.738 (0.699-0.774) with optimal cut-off values of 24.6 ng/mL, 111 IU/mL, 27 IU/mL, and 2.979, respectively. Of the four biomarkers, AFP and NLR showed comparable specificity (0.881 and 0.858) and sensitivity (0.561 and 0.539). The combination of AFP and NLR showed the highest AUC (0.769) with a significantly higher sensitivity (0.767) and a lower specificity (0.773) compared to AFP or NLR alone, and it had the highest sum of sensitivity and specificity (1.54) among all combinations. In patients with AFP < 20 ng/mL, the NLR showed the highest AUC and combination with other markers did not improve the diagnostic accuracy.

Conclusions: Our data indicate that the combination of AFP and NLR offers better diagnostic performance than either marker alone for differentiating HCC from liver disease, which may benefit clinical screening.

Citing Articles

Diagnosis and treatment of hepatocellular carcinoma with pelvic metastasis expressing AFP: a case report.

Huang L, Wang Z, Lu J Front Oncol. 2025; 14():1489725.

PMID: 39839797 PMC: 11746055. DOI: 10.3389/fonc.2024.1489725.


Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy.

DAbundo L, Bassi C, Callegari E, Moshiri F, Guerriero P, Michilli A Sci Rep. 2024; 14(1):18551.

PMID: 39122875 PMC: 11315904. DOI: 10.1038/s41598-024-69548-4.


MRI Radiomics Combined with Clinicopathological Factors for Predicting 3-Year Overall Survival of Hepatocellular Carcinoma After Hepatectomy.

Kuang F, Gao Y, Zhou Q, Lu C, Lin Q, Al Mamun A J Hepatocell Carcinoma. 2024; 11:1445-1457.

PMID: 39050810 PMC: 11268741. DOI: 10.2147/JHC.S464916.


The chemokine CCL20 can assist AFP in serological diagnosis of hepatocellular carcinoma.

Deng Q, Zhang X, Wan X, Zheng X, Wang H, Zhao J Heliyon. 2024; 10(5):e26774.

PMID: 38439882 PMC: 10909724. DOI: 10.1016/j.heliyon.2024.e26774.


Circulating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings.

Pan A, Truong T, Su Y, Dao D Diagnostics (Basel). 2023; 13(4).

PMID: 36832164 PMC: 9954913. DOI: 10.3390/diagnostics13040676.


References
1.
Llovet J, Bruix J . Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol. 2001; 14(6):991-1008. DOI: 10.1053/bega.2000.0143. View

2.
Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View

3.
Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

4.
Unitt E, Marshall A, Gelson W, Rushbrook S, Davies S, Vowler S . Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol. 2006; 45(2):246-53. DOI: 10.1016/j.jhep.2005.12.027. View

5.
Perz J, Armstrong G, Farrington L, Hutin Y, Bell B . The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4):529-38. DOI: 10.1016/j.jhep.2006.05.013. View